Table 3:
Results from Mutinomial/Multivariable Logistic Regression†
|
Any Follow Up vs. No Follow Up‡ Adj OR (95% CI) |
Any Treatment vs. No Treatment‡ Adj OR (95% CI) |
Bevacizumab vs. No Treatment Adj OR (95% CI) |
Ranibizumab/Aflibercept vs. No Treatment Adj OR (95% CI) |
Focal Laser vs. No Treatment Adj OR (95% CI) |
Any Anti-VEGF vs. No Treatment Adj OR (95% CI) |
Ranibizumab/Aflibercept vs. Bevacizumab Adj OR (95% CI) |
p-value* | |
|---|---|---|---|---|---|---|---|---|
| DCSS (1-2 ref) | <0.001 | |||||||
| 3 | 0.96 (0.83 - 1.12) | 1.01 (0.83 - 1.23) | 1.29 (0.95 - 1.74) | 1.06 (0.64 - 1.75) | 0.95 (0.70 - 1.29) | 1.23 (0.93 - 1.63) | 0.81 (0.46 - 1.42) | |
| 4-5 | 1.20 (1.05 - 1.38) | 0.92 (0.76 - 1.13) | 1.21 (0.93 - 1.58) | 1.12 (0.73 - 1.71) | 0.86 (0.66 - 1.13) | 1.19 (0.94 - 1.52) | 0.99 (0.62 - 1.61) | |
| >5 | 1.46 (1.27 - 1.68) | 0.79 (0.63 - 0.97) | 1.20 (0.93 - 1.56) | 1.35 (0.90 - 2.03) | 0.73 (0.55 - 0.96) | 1.24 (0.98 - 1.57) | 1.14 (0.72 - 1.82) | |
| Geographic region (Up Midwest Ref) | <0.001 | |||||||
| Southern Midwest | 0.98 (0.83 - 1.16) | 1.30 (1.03 - 1.64) | 1.40 (1.04 - 1.87) | 1.08 (0.64 - 1.81) | 1.39 (1.01 - 1.89) | 1.35 (1.02 - 1.77) | 0.73 (0.42 - 1.28) | |
| Northeast | 0.86 (0.73 - 1.01) | 0.82 (0.64 - 1.05) | 0.47 (0.33 - 0.67) | 1.11 (0.67 - 1.82) | 1.26 (0.91 - 1.74) | 0.60 (0.44 - 0.82) | 2.39 (1.31 - 4.37) | |
| Mountain | 0.90 (0.72 - 1.11) | 1.00 (0.73 - 1.36) | 1.47 (1.02 - 2.11) | 0.66 (0.30 - 1.46) | 0.67 (0.41 - 1.07) | 1.34 (0.94 - 1.90) | 0.41 (0.18 - 0.94) | |
| Pacific | 1.01 (0.81 - 1.26) | 1.05 (0.76 - 1.45) | 1.34 (0.90 - 1.98) | 1.05 (0.51 - 2.17) | 0.72 (0.45 - 1.17) | 1.30 (0.90 - 1.88) | 0.73 (0.33 - 1.61) | |
| South Atlantic | 0.90 (0.77 - 1.05) | 1.03 (0.83 - 1.27) | 0.87 (0.66 - 1.16) | 1.60 (1.05 - 2.45) | 1.06 (0.79 - 1.42) | 1.04 (0.81 - 1.34) | 1.82 (1.13 - 2.96) | |
| Unknown | 0.43 (0.13 - 1.41) | 0.46 (0.05 - 4.48) | 0.85 (0.09 - 8.46) | Not calculable | Not calculable | 0.77 (0.08 - 7.58) | Not calculable | |
| High Deductible Ins | 0.87 (0.72 - 1.05) | 0.84 (0.64 - 1.10) | 0.89 (0.62 - 1.28) | 0.94 (0.54 - 1.66) | 0.76 (0.54 - 1.08) | 0.89 (0.63 - 1.24) | 0.94 (0.50 - 1.78) | 0.15 |
| Insurance type (HMO Ref) | 0.02 | |||||||
| Point of Service | 1.09 (0.91 - 1.30) | 1.05 (0.81 - 1.36) | 0.96 (0.69 - 1.34) | 1.19 (0.68 - 2.09) | 0.99 (0.70 - 1.40) | 1.04 (0.76 - 1.41) | 1.42 (0.75 - 2.70) | |
| Exclusive Provid Org | 0.95 (0.73 - 1.22) | 1.25 (0.85 - 1.83) | 1.14 (0.69 - 1.90) | 1.38 (0.61 - 3.13) | 1.10 (0.66 - 1.85) | 1.18 (0.74 - 1.87) | 1.16 (0.46 - 2.92) | |
| Preferred Provid Org | 1.42 (1.12 - 1.79) | 1.18 (0.84 - 1.65) | 1.52 (0.98 - 2.35) | 1.31 (0.66 - 2.61) | 0.87 (0.54 - 1.40) | 1.45 (0.97 - 2.15) | 0.76 (0.34 - 1.69) | |
| Other | 1.18 (1.01 - 1.38) | 1.14 (0.91 - 1.43) | 1.14 (0.86 - 1.52) | 1.29 (0.78 - 2.13) | 0.98 (0.72 - 1.34) | 1.17 (0.89 - 1.52) | 1.00 (0.57 - 1.76) | |
| Copay ($0 ref) | <0.001 | |||||||
| $1 or more | 0.63 (0.56 - 0.71) | 0.60 (0.51 - 0.71) | 0.73 (0.59 - 0.91) | 0.70 (0.49 - 0.99) | 0.44 (0.35 - 0.55) | 0.72 (0.59 - 0.88) | 0.98 (0.66 - 1.47) | |
†
Results of different models are presented in this table with comparison groups designated in the header. Different models are represented by each of the boxed/unboxed columns. All models in addition to the variables listed also controlled for age, gender, race, education level, yearly income and cohort year
‡
Model also included patients who received steroid injection or an injection with the drug not noted
*
p-values represent the lowest value across all models. All significant variables are denoted by bold Italics type and normal type denotes insignificant association
DCSS= Diabetic Complications Severity Score